The main contents of the instructions for Selegiline/Imidopir

1. Name: Selegiline Hydrochloride Tablets,Selegiline, Imidopyr, Eldepryl

2. Indications:

The indications of Selegiline/midopid are mainly for patients with Parkinson's disease who are receiving levodopa/carbidopa treatment. Such patients may experience a decline in the quality of their response to therapy during long-term treatment. At this time, selegiline hydrochloride tablets can be used as an auxiliary treatment drug. Therefore, the use of selegiline hydrochloride tablets should be combined with levodopa to achieve the best therapeutic effect.

3. Usage and dosage:

The recommended dosage of selegiline hydrochloride tablets is 10 mg per day , usually divided into 5 mg each for breakfast and lunch. This dosing regimen helps maintain stable blood drug concentrations and ensures maximum drug efficacy. Research shows that exceeding this dose does not provide additional benefit and may increase the risk of side effects, so higher doses are generally not recommended. In the early stages of treatment with Selegiline Hydrochloride Tablets, doctors may adjust the dosage of levodopa/carbidopa in a timely manner based on the patient's specific conditions. Based on the results of placebo-controlled trials, the dose of levodopa/carbidopa can generally be reduced by 10% to 30% in patients receiving selegiline hydrochloride tablets. During continued use of selegiline HCl, further dose reduction of levodopa/carbidopa is possible.

4. Adverse reactions:

During the clinical use of selegiline hydrochloride tablets, some patients may experience adverse reactions, leading to discontinuation of medication. According to prospective pre-marketing studies, common adverse reactions include but are not limited to: nausea, hallucinations, confusion, depression, loss of balance, insomnia, orthostatic hypotension, etc. Other adverse reactions, such as agitation, arrhythmia, bradykinesia, chorea, delusions, hypertension, new or worsened angina, and syncope, although occurring less frequently, still require attention. In addition, a small number of patients may experience uncomfortable symptoms such as ankle edema, anxiety, constipation, drowsiness, and dystonia.

5. Storage:

Storage conditions for selegiline tablets are very important. Store them at a temperature of20° to 25°C (68° to 77°F). Medication should be placed in a closed, light-resistant container with a childproof cover to prevent accidental ingestion by children. During storage, moisture and high temperature environments need to be avoided to ensure the effectiveness and safety of the drug.

6. Taboo:

This drug is contraindicated in patients with known hypersensitivity to selegiline hydrochloride tablets. In addition, the combined use of selegiline hydrochloride tablets and meperidine (Meperidine) is absolutely contraindicated, and this contraindication is usually extended to the use of other opioids to avoid possible serious adverse reactions.

7. Mechanism of action:

The mechanism of action of selegiline is not fully understood, but inhibiting the activity of monoamine oxidase type B (MAO-B) is considered to be its main therapeutic mechanism. MAO is an intracellular enzyme associated with the outer membrane of mitochondria and is primarily responsible for metabolizing neurotransmitters such as dopamine. By acting as a substrate for MAO, selegiline hydrochloride tablets are converted into an active moiety that irreversibly binds to the active site of the enzyme and the essential FAD cofactor, thereby inhibiting the activity of MAO. Since selegiline hydrochloride tablets have a stronger affinity for the active site of type B MAO than for type A, at the recommended dose, it can selectively inhibit the activity of type B MAO, thereby increasing the concentration of dopamine in the brain, improving the symptoms of Parkinson's disease patients, and improving the quality of life.

Reference: https://www.drugs.com/mtm/selegiline.html